Related Experiment Video
Updated: Sep 26, 2025
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Sclerostin immunohistochemical staining in surgically treated giant cell tumor of bone
Sean P Kelly1, Dipak B Ramkumar2,3, Zachary S Peacock4
1Department of Orthopaedic Surgery, Tripler Army Medical Center, Honolulu, Hawaii, USA.
Background:
Giant cell tumor of bone (GCTB) is a destructive lesion with a high potential for recurrence. RANK-ligand targeted therapy has provided promising, yet mixed results. Sclerostin (SOST) inhibition results in a net anabolic response and is currently used in the treatment of osteoporosis. The application to GCTB is unknown.
Objectives:
We sought to determine if GCTB stained for SOST on immunohistochemistry and correlate its expression with predictor variables.
Methods:
All patients at a single institution undergoing surgery for GCTB between 1993 and 2008 with a minimum of 6 months follow-up were included. Primary outcomes included the presence of SOST staining, secondary outcomes included the correlation of patient and tumor-specific predictor variables.
Results:
SOST antibody staining of any cell type was present in 47 of 48 cases (97.9%). Positivity of the stromal cells was present in 39 of 48 cases (81.3%) and was associated with radiographic aggressiveness (p = 0.023), symptomatic presentation (p = 0.032), prior surgery (p = 0.005), and patient age (p = 0.034). Positivity of giant cells was present in 41 of 48 cases (85.4%) and was not significant with predictive factors.
Conclusions:
Sclerostin staining in GCTB is a novel finding and warrants further research to define the role of sclerostin as a prognostic factor and therapeutic target.
Insights
Sclerostin (SOST) is present in most giant cell tumors of bone (GCTB). SOST expression in GCTB stromal cells correlates with aggressive features, suggesting its potential as a prognostic factor and therapeutic target.
Area of Science:
- Orthopedics
- Oncology
- Bone Biology
Background:
- Giant cell tumor of bone (GCTB) is a destructive bone lesion with high recurrence rates.
- Current therapies, like RANK-ligand inhibitors, show variable efficacy.
- Sclerostin (SOST) inhibition promotes bone anabolism and is used for osteoporosis; its role in GCTB is unexplored.
Purpose of the Study:
- To investigate the presence of sclerostin (SOST) in GCTB using immunohistochemistry.
- To correlate SOST expression with clinical and radiographic predictor variables in GCTB patients.
Main Methods:
- Retrospective analysis of GCTB surgical cases from 1993-2008 with at least 6 months follow-up.
- Immunohistochemistry was used to detect SOST staining in tumor cells.
- Statistical analysis correlated SOST positivity with patient age, tumor aggressiveness, and treatment history.
Main Results:
- Sclerostin (SOST) staining was detected in 97.9% of GCTB cases.
- Stromal cell SOST positivity (81.3%) correlated with radiographic aggressiveness, symptomatic presentation, prior surgery, and patient age.
- Giant cell SOST positivity (85.4%) did not show significant correlation with predictive factors.
Conclusions:
- Sclerostin (SOST) expression is a novel finding in giant cell tumors of bone (GCTB).
- SOST staining in GCTB warrants further investigation.
- Sclerostin may serve as a prognostic indicator and a potential therapeutic target for GCTB.
More Related Videos
11:15A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
07:13Application of Retinoic Acid to Obtain Osteocytes Cultures from Primary Mouse Osteoblasts
Published on: May 13, 2014